Cargando…

Treatment and prognostic analysis of patients with leptomeningeal metastases from non-small cell lung cancer

BACKGROUND: Leptomeningeal metastases (LM) from non-small cell lung cancer (NSCLC) are associated with poor prognosis and optimal treatment for this subgroup of NSCLC patients is controversial. The purpose of this study is to evaluate treatment options and prognostic factors of NSCLC patients with L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Qinghua, Chen, Xiu, Qian, Danwen, Wang, Yongsheng, Meng, Shuyan, Liu, Hui, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511317/ https://www.ncbi.nlm.nih.gov/pubmed/26273394 http://dx.doi.org/10.1111/1759-7714.12188

Ejemplares similares

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

Analyses of prognostic factors in cases of non-small cell lung cancer with multiple brain metastases
por: Gong, Xiaomei, et al.
Publicado: (2016)

Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing
por: Yang, Hainan, et al.
Publicado: (2022)

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
por: Yufen, Xu, et al.
Publicado: (2016)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
por: Niu, Hardy, et al.
Publicado: (2017)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
por: Li, Huiying, et al.
Publicado: (2019)

Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: A case report and review of the literature
por: BAI, CHONG, et al.
Publicado: (2013)

Characteristics and outcomes of non-Hodgkin’s lymphoma patients with leptomeningeal metastases
por: Meng, Xiangrui, et al.
Publicado: (2018)

Editorial: Brain and leptomeningeal metastases in lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2023)

Invasion of small cell lung cancer into the limbic system from leptomeningeal metastases
por: Higo, Hisao, et al.
Publicado: (2021)

Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy
por: Llinás-Quintero, Néstor, et al.
Publicado: (2019)

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis
por: Wen, Lei, et al.
Publicado: (2023)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
por: Zhang, Hui, et al.
Publicado: (2022)

Ovarian Adenocarcinoma With Leptomeningeal Metastases
por: Bayas, Angel, et al.
Publicado: (2022)

Autoimmune limbic encephalitis combined with leptomeningeal metastases of non-small cell lung cancer: treatment response to osimertinib, immunoglobulin, rituximab, and tocilizumab
por: Lee, Seolah, et al.
Publicado: (2023)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer
por: Jackman, David M., et al.
Publicado: (2015)

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
por: Nanjo, Shigeki, et al.
Publicado: (2018)

A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
por: Pan, Zhenyu, et al.
Publicado: (2019)

Bedside ocular ultrasonography for diagnosing increased intracranial pressure in patients with leptomeningeal metastases from non‐small‐cell lung cancer
por: Jiang, Cheng, et al.
Publicado: (2022)

Helical tomotherapy in patients with leptomeningeal metastases
por: Schiopu, Sanziana RI, et al.
Publicado: (2018)

Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases
por: Qiao, Meng, et al.
Publicado: (2021)

Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution
por: Yang, Hainan, et al.
Publicado: (2022)

Brain parenchymal and leptomeningeal metastasis in non-small cell lung cancer
por: Li, Qing, et al.
Publicado: (2022)

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
por: Zheng, Mei-Mei, et al.
Publicado: (2022)

Prognostic significance of molecular characteristics of cerebrospinal fluid for non‐small cell lung cancer patients with leptomeningeal metastasis
por: Li, Ning, et al.
Publicado: (2019)

MMAP-04 CYTOTOXIC, TUMOR-HOMING INDUCED NEURAL STEM CELLS AS AN ADJUVANT TO RADIATION IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER LEPTOMENINGEAL METASTASES
por: Mercer-Smith, Alison, et al.
Publicado: (2022)

Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
por: Chen, Yu, et al.
Publicado: (2021)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
por: Yang, James C.H., et al.
Publicado: (2020)

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
por: Xu, Hongyu, et al.
Publicado: (2020)

Intrathecal chemotherapy as a treatment for leptomeningeal metastasis of non-small cell lung cancer: A pooled analysis
por: Wu, Ya-Lan, et al.
Publicado: (2016)

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis
por: Jiang, Tao, et al.
Publicado: (2016)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Anorectal Cancer with Bone Marrow and Leptomeningeal Metastases
por: Zeeneldin, Ahmed, et al.
Publicado: (2018)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Dural and Leptomeningeal Spine Metastases of Breast Cancer
por: Matos, Fernando, et al.
Publicado: (2019)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mibvl6cbtqjteeu17j0vogrfmd